Placenta cell therapy shows promise for tough transplant complication
NCT ID NCT04118556
First seen May 20, 2026 · Last updated Jun 22, 2026 · Updated 4 times
Summary
This trial tested a treatment made from placenta cells (called decidua stroma cells) in 12 adults who had severe graft-versus-host disease (GVHD) after a stem cell transplant and did not respond to steroids. Patients received two doses of the cells or the best available standard therapy. The goal was to see if the cell treatment was safe and could improve outcomes by day 56.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD,ACUTE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Copenhagen Univerity Hospital
Copenhagen, 2300, Denmark
-
Lund University Hospital
Lund, SE-221 85, Sweden
-
Oslo University Hospital
Oslo, NO-0424, Norway
-
Uppsala University Hospital
Uppsala, SE-75185, Sweden
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
placenta-derived decidua stroma cells (DSC)
What this could lead to
If it works, this could offer a new treatment option for patients with severe graft-versus-host disease that does not respond to steroids.
What could go wrong
This is a small, early-phase trial (only 12 patients) that was terminated, so results are limited. The treatment may not work better than existing options and carries risks like infection or infusion reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.